Where we seem to disagree is on the impact of a positive outcome from SARAH. Phase 3 is the gold standard -- I think there are likely to be many clinicians out there who will be drawn to SIRT on the basis of a successful phase 3. So I think we will make up a lot of lost ground if the news is good. Good Foxfire/Foxfire Global results should produce new sp highs. IMHO, Cheers.
SRX Price at posting:
$14.93 Sentiment: Hold Disclosure: Held
